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Background: Previous in vitro experiments have demonstrated that PGF2α reduced 
proliferation and adipogenesis in a murine cell line and human orbital fibroblasts 
derived from subjects with inactive Graves’ orbitopathy (GO). The objective of this 
study was to determine if the PGF2α analogue Bimatoprost is effective at reducing 
proptosis in this population. 
Methods: A randomized controlled double-masked crossover trial was conducted in a 
single tertiary care academic medical center. Patients with longstanding, inactive GO 
but persistent proptosis (> 20 mm in at least one eye) were recruited. Allowing for a 
15% dropout rate, 31 patients (26 females) were randomized in order to identify a 
treatment effect of 2.0 mm (p=0.05, two-sided paired t-test, power 0.88). Following 
informed consent, participants were randomized to receive Bimatoprost or placebo for 
three months after which they underwent a two-month washout, before switching to 
the opposite treatment. The primary outcome was the change in exophthalmometry 
readings over the two 3-month treatment periods.  
Results: The mean exophthalmometer at baseline was 23.6 (range 20.0-30.5) mm and 
the mean age was 55 (range 28-74) years. The median duration of GO was 7.6 (IQR 
3.6-12.3) years. The majority were still suffering from diplopia (61.3%) with bilateral 
involvement (61.3%). Using multilevel modeling adjusted for baseline, period and 
carryover, Bimatoprost resulted in a -0.17 mm (reduction) exophthalmometry change 
(95% CI -0.67 to +0.32) p=0.490. Intraocular pressure was reduced -2.7 mmHg (95% 
CI -4.0 to -1.4) p=0.0070. One patient showed periorbital fat atrophy (PAP) on 




photographic images (all subjects) and subgroup analysis on monocular disease 
(n=12) did not show any apparent benefit. 
Conclusion: In inactive GO, Bimatoprost treatment over a 3-month period does not 





Graves’ orbitopathy (GO) is the commonest extrathyroidal manifestation of Graves’ 
hyperthyroidism. Proptosis may persist after inflammation has subsided in the late 
“burnt out” phase of GO and the persistent disfigured appearance of the eyes is a 
source of significant psychological distress and impaired quality of life for sufferers (1). 
There are no specific medical treatments that target orbital volume reduction in late-
stage disease. A UK nationwide survey of patients with GO revealed low satisfaction 
levels with existing therapies (2). 
The main pathological features of GO include expansion of orbital tissue fat, muscle, 
mononuclear cell infiltration of orbital connective tissue and extraocular muscle, and 
tissue remodeling, a process that can culminate in fibrosis and diminished eye motility 
(3). A key mechanism underlying GO is an increase in adipogenesis and muscle 
associated secretion of glycosaminoglycans (GAG) in the orbit, resulting in an 
increase in orbital volume and exophthalmos (protrusion of the eye) (4, 5). The 
opposite effect, enophthalmos (recession of the eye into the orbit), has been described 
in patients with glaucoma treated with daily Bimatoprost (prostaglandin F2 alpha, 
PGF2α), a prostaglandin analogue used topically in the management of intraocular 
hypertension (glaucoma). Cases of enophthalmos developing in patients treated with 
Bimatoprost and other PGF2α analogues have been reported worldwide, albeit in small 
numbers (6-10). This side effect is more noticeable if only one eye is exposed to 
treatment as the treated eye is easily comparable with the unexposed eye. However, 
since most patients receive treatment to both eyes it is possible that the incidence of 




A possible mechanism by which PGF2α agonists might produce enophthalmos is 
through reduction of orbital fat volume (6). A PGF2α receptor agonist has been shown 
to be a potent inhibitor of adipose tissue differentiation in new-born rat precursor cells 
(11). This raises the possibility that PGF2α exerts direct effects on adipose tissue 
precursors. We have confirmed this finding in in vitro studies in our laboratory using 
3T3-L1 cell lines and human primary orbital fibroblast cultures (12). This is further 
supported by Eftekhari et al. who reported that retrobulbar Bimatoprost injections in 
rats showed histologic evidence of orbital fat atrophy (13). Thus, PGF2α agonists may 
be effective in reducing orbital fat expansion, ameliorating proptosis, and thus 
improving quality of life in patients with active and/or inactive disease. 
Rehabilitative surgery is the mainstay of treatment for the late disease phase. 
However, surgery is not always successful in reducing proptosis and carries the 
associated risks of anesthesia and local complications (14). Recently Teprotumumab, 
a human monoclonal antibody inhibitor of IGF-1R has been shown to reduce proptosis 
in patients with active GO (15), whilst radiotherapy is of questionable benefit in 
conjunction with steroids (16). However, there remains a major unmet need for 
medical therapies to reduce residual proptosis in the late-phase (inactive) of GO, a 
disease stage in which disfigurement and impairment of ocular function persist after 
resolution of the initial inflammatory process and which affects 5-10 times as many 
people as the early active phase (17). In our in vitro study, the majority of samples 
studies were from patients with inactive GO, and PGF2α was noted to reduce 
proliferation and adipogenesis in orbital fibroblasts from both GO and non-GO tissue 
(12). Even in “burnt out” disease, orbital fibroblasts from GO have a higher proliferation 




a randomized double-masked cross-over clinical study to evaluate the impact of 
Bimatoprost at reducing proptosis in patients with GO.  
 
METHODS 
The trial was conducted according to the protocol and in compliance with the principles 
of the Declaration of Helsinki (1996), the principles of Good Clinical Practice (GCP) 
and in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004, 
as amended in 2006, the Research Governance Framework for Health and Social 
Care, the Data Protection Act 1998 and other regulatory requirements as appropriate. 
The trial has been approved by a local NHS Research Ethics Committee (REC, 
registration number: 14/WA/0081), the Medicines and Healthcare Products Regulatory 
Agency (MHRA, registration number: 21323/0043/001-0001) and is registered with 
ClinicalTrials.gov (registration number: NCT02059655) and the International standard 
randomized controlled trial network (ISRCTN, registration number: 
ISRCTN46696624).  
This was a single center randomized controlled double-masked crossover trial of 
Bimatoprost in GO. Allocation of subjects was by remote computerized web-based 
randomization and minimization over 2 identified factors (degree of proptosis and 
uni/bilateral eyes involvement) to ensure a balance between the 2 trial arms.  
Patients were recruited from the multidisciplinary GO clinic at University Hospital of 
Wales. All patients had had a previous diagnosis of GO defined by the presence of 




extraocular muscle dysfunction, corneal abnormalities, and optic nerve involvement. 
The inclusion criteria were stable GO with no reported change in proptosis for at least 
6 months, inactive disease with a clinical activity score <3, proptosis (subjective 
unilateral proptosis confirmed by asymmetry in exophthalmometry of >2 mm or greater 
than 20 mm on exophthalmometry measurement in one eye), euthyroid (FT3 and FT4 
in the reference range) and, if female, using a reliable form of contraception during the 
trial. The exclusion criteria were age less than 18 years old, dysthyroid optic 
neuropathy, pregnancy/lactation, on therapy for glaucoma, systemic steroid use, 
patients with risk factors for cystoid macular edema, iritis or uveitis and allergies to 
Bimatoprost or preservative.  Patients were assessed at screening visit at least 2 
weeks prior to a first trial visit to ensure that they had inactive disease.  Patients were 
allocated either Bimatoprost or placebo for 3 months, followed by 2 months washout 
period before crossing over to the opposite treatment. Bimatoprost 0.03% (Lumigan® 
Allergan) or placebo (Blumont Healthcare) was administered at a dose of one drop in 
the affected eye/eyes once daily between 18:00 - midnight starting from the day of 
allocation. To enhance masking, the placebo contained artificial tears with a similar 
preservative (Benzalkonium chloride) which will replicate any mild stinging sensation 
experienced with Bimatoprost. Patients were allowed to use preservative free eye 
drops for symptomatic dry eyes if needed during the trial which had to be applied at 
least 30 minutes before/after trial drops application. No other eye drops were allowed 
during the trial period.  
The primary outcome was the change in proptosis with Bimatoprost using the mean 
improvement of the two eyes where both have been treated. A change of > 2.0 mm in 




deviation of 2.5 mm in proptosis measurements in patients with GO as previously 
reported [19, 20], we calculated that 26 participants would be needed to be able to 
identify a treatment effect of 2.0 mm as statistically significant (p=0.05, two-sided 
paired t-test, power 0.88). Allowing for a 15% dropout rate/incomplete datasets, we 
recruited 31 participants.  
At each visit, patients underwent ophthalmological assessment including assessment 
of proptosis (using an Oculus© exophthalmometer), intraocular pressure in primary 
position and up gaze, logMAR visual acuity, clinical activity score (CAS), palpebral 
aperture, Gorman’s diplopia score, corneal integrity, quality of life questionnaires (GO 
quality of life questionnaire (GO-QOL) and EQ-5D-5L) and health economic 
assessment using modified client service receipt inventory (CSRI) for GO (see 
supplementary material - BIMA protocol). Color photographs of the eye in the lateral 
and anterior views were taken according to a standard operating procedure (see 
supplementary material - SOP). Photograph exophthalmometry measurements were 
made following 200% magnification from standard view either from lateral canthus or 
nasal bridge to the corneal apex by a masked assessor. Any adverse events were 
recorded in the patient’s diary. Thyroid function tests (TSH, FT3, FT4) were performed 
at the beginning, middle and end of trial visits to ensure patients remained euthyroid. 
Secondary outcomes were change in GO-QOL, change in intraocular pressures (IOP) 
in primary and chin forward position, side effect profiles of Bimatoprost, and health 
economic evaluation. The ophthalmology assessment was carried out by either one 
of two assessing ophthalmologists. We conducted an initial exophthalmometer 
alignment phase whereby the assessors were calibrated by multiple 




adjustments were made to ensure their readings were comparable. Subjects were not 
necessarily assessed by the same assessor at each time point. In order to ensure 
maintenance of masking, during each trial visit the assessors did not have access to 
baseline values or any prior measurements and clinical notes. 
The mean change in proptosis measurement in the placebo phase and Bimatoprost 
phase was compared with a paired t-test. This was carried out using the mean 
improvement of the two eyes where both have been treated or the change in one eye 
where only one was treated. Multilevel model in STATA version 12.1 (STATACORP, 
College Station, TX)  using demographic and clinical variables (including baseline, the 
order of treatment and carryover effects) was also used to adjust for unexplained 
variance and in order to obtain better estimates of effect size with tighter confidence 
intervals. The results are expressed as an effect in millimeters from the treatment arm 
controlling for the placebo effect with 95% confidence intervals (95% CI) and p-values. 
Secondary and other outcomes were summarized with descriptive statistics.  
There were 3 patients who were deemed to be protocol non-compliant with inclusion 
criteria who had FT4 levels above the reference range with normal FT3 during the 
screening period. This was due to a misinterpretation of the inclusion criteria whereby 
the definition of euthyroid was FT3 and FT4 in the reference range. Instead, the result 
of either FT3 or FT4 was used to define the euthyroid state. These three patients were 
clinically euthyroid during randomization. A sensitivity analysis was done after the 






Recruitment and retention 
Seventy-two patients were invited initially of which 33 agreed for the trial enrolment. 
One patient was ineligible on screening and one patient chose not to take part due to 
fear that Bimatoprost might change her iris color. Thirty-one patients were 
subsequently randomized and underwent the first phase of the trial successfully. 
Unfortunately, one patient from the Bimatoprost starting group died at the end of first 
washout period due to pulmonary embolism which was not considered to be related 
to the investigational product. Therefore, 30 patients were entered into the second 
phase of the trial. One patient from the placebo starting group did not return for visit 4 
(end of second phase assessment) due to the withdrawal of consent. Twenty-nine 
patients entered the second washout phase and completed the trial (Figure 1).  
 
Demographic and baseline characteristics 
Out of 31 patients, there was a female preponderance with a 5:1 ratio and a mean age 
of 55.2 (range 28-74) years. The median duration of GO was 7.6 (IQR 3.6-12.4) years. 
The majority were smokers at diagnosis (74.2%), but this reduced to 38.7% after the 
diagnosis. 61% were still suffering from diplopia (19/31) and 19/31 (61%) had bilateral 
involvement. There was a good balance between the 2 treatment allocations with 
some differences in smoking history but not at trial entry and more patients with 
constant diplopia in the Bimatoprost first starting group (Table 1). Thyroid function 





Fifteen non-trial patients were assessed by the 2 assessors by exophthalmometry 
after a period of calibration between assessors involving 5 patients. Compared to 
assessor 1, the regression coefficient of assessor 2 was 0.93 (95% CI 0.83 to 1.03) 
mm. There was a positive Pearson correlation with r=0.9652 (p<0.0001) between the 
2 assessors (Supplement Figure 1 and 2). 
Primary outcome analysis 
The mean baseline exophthalmometer readings of treated eyes in the Bimatoprost 
starting group was 24.1 (SD 2.9) mm and 23.1 (1.9) mm in the placebo starting group 
(Table 1). The mean change across all affected eyes in the Bimatoprost phase was 
+0.17 mm (95% CI -0.35 to +0.69) versus +0.26 mm (95% CI -0.51 to +1.03) in the 
placebo phase. This was not statistically different with a p value = 0.845 (Figure 2). A 
sensitivity analysis was done after exclusion of the three protocol non-compliant 
subjects. There was no difference between the 2 groups p=0.727. Using pkcross 
function on the STATA, there were no period (p=0.38) or carryover (p=0.46) effects 
observed.   
Multilevel modelling 
Data were also analyzed using a multilevel model in STATA which will also enables to 
use one data point for those patients who were unwilling or unable to proceed to the 
second phase of the protocol, thus using all available data as efficiently as possible.  





Crude analysis adjusted for baseline (model 1) did not show any treatment effect on 
the exophthalmometer readings with a coefficient of -0.27 mm (95% CI -1.43 to +0.89, 
p=0.648). Adding multilevel modelling correcting for baseline and phase of treatment 
(model 2) resulted in a treatment coefficient of -0.17 mm (95% CI -0.67 to +0.32), again 
not statistically significant p=0.490. Carryover adjustment was omitted because of 
collinearity with the phase of treatment. Adding the assessors to the model did not 
improve the model with a treatment effect of -0.16 mm (95% CI -0.65 to 0.33, p=0.531) 
and an assessor coefficient of -0.34 mm (95% CI -0.96 to 0.27, p= 0.274). Removing 
3 patients with protocol deviation resulted in a model 2 treatment coefficient of -0.06 
mm (95% CI -0.56 to +0.45, p=0.827) and a model 3 treatment coefficient of -0.04 mm 
(95% CI -0.55 to +0.46, p= 0.861). Using response to 10% drop in IOP as a surrogate 
marker for compliance showed no statistically significant treatment effect on proptosis 
as measured on the exophthalmometer (Table 2).  
Exophthalmometer change in patients with unilateral proptosis 
There were 12 patients with unilateral proptosis. In these patients, only one eye with 
proptosis was treated whilst the other eye was not treated and served as a control. 
Analysis of the exophthalmometer reading revealed predicted baseline 
exophthalmometer differences with a higher exophthalmometer mean in the treated 
eye of 22.17 mm (95% CI 21.16 to 23.17) versus 20.33 mm (95% CI 19.14 to 21.52) 
in the untreated eye (p=0.0032). Treatment with Bimatoprost did not result in a 
statistically significant reduction in exophthalmometer results with a mean change of 
+0.08 mm (95% CI -0.66 to +0.82) in the treated eye compared to 0.67 mm (95% CI -




Exophthalmometry and photographic assessment correlations  
Proptosis measurements were also made by photographic assessment of the patient 
photos taken during the trial. The measurements were taken either from the lateral 
canthus or nasal bridge to the corneal apex by a masked assessor (Figure 3). All data 
from 5 visits were used for this analysis. Results of the Spearman correlation indicated 
that there was a significant positive association between exophthalmometer and 
lateral canthus measurements (Spearman rho 0.609, p<0.0001). There was a 
significant negative correlation between exophthalmometer and nasal bridge 
measurements (Spearman rho -0.396, p<0.0001) (see Figure 4 and Figure 5). The 
later finding was expected as the measurement was taken from nasal bridge to corneal 
apex, i.e. the more proptosis, the lesser the distance between the corneal apex to the 
nasal bridge. 
There was no difference between placebo and Bimatoprost with regard to photo 
measurement results of the lateral canthus to corneal apex distance with placebo 
(mean change of +1.30 mm; 95% CI -0.74 to +3.35) compared to Bimatoprost +0.98 
mm (95% CI -1.25 to +3.20) (p=0.8160). Similarly, there was no difference between 
placebo and Bimatoprost nasal bridge to corneal apex measurement results with 
placebo treatment resulting in a mean change of -0.50 mm (95% CI -4.18 to +4.08) 
compared to Bimatoprost with a mean change of +1.30 mm (95% CI -5.65 to +8.25) 
(p=0.6870). There was no significant change observed in the subset of patients with 
unilateral proptosis (n=12) with Bimatoprost treatment resulting in a lateral cantus 
measurement change of -0.32 mm (95% CI -4.41 to +3.76) versus untreated of +1.09 




a nasal bridge measurement change of +3.10 mm (95% CI -13.53 to +19.73) 
compared to untreated eye of +6.43 mm (96% CI -3.99 to +16.86) (p=0.6318). 
Secondary outcome analysis 
In general, patients scored highly on the total visual score using the GO-QOL 
questionnaire throughout trial visits with a range of mean total visual scores of 79 to 
85. With regard to treatment, there was no change in the total visual scores. The 
change was calculated by subtracting post-treatment score against baseline score. A 
positive value would indicate an improvement in the quality of life and a change of at 
least 6 points was considered a minimal clinically important difference. The mean 
changes for Bimatoprost was 0.8 (95% -7.1 to 8.7) versus placebo -0.6 (95% CI -6.5 
to 5.2) (p=0.7930). There was a good negative correlation between the Gorman 
diplopia score and the total visual score (Spearman’s rho -0.5118, p<0.0001). This 
negative correlation persisted even after removing patients treated with prisms 
(Spearman rho -0.5111, p<0.0001). 
Patients scored lower throughout trial visits with regard to total appearance score with 
the mean ranging from 52 to 58. No change in total appearance score was seen at 3 
months after Bimatoprost treatment with a mean of 0.4 (95% CI -3.6 to 4.5) versus 
placebo 2.2 (95% CI -5.2 to 9.5) (p=0. 0.6897). There was no correlation between the 
Gorman diplopia score and the total appearance score (Spearman’s rho –0.0785, 
p=0.3396). This correlation became significant after removing patients treated with 




During trial visits, the mean IOP measured in the primary position was within the 
normal reference range between 16 to 18 mmHg. As expected, Bimatoprost caused a 
reduction in IOP with a mean change of -2.7 mmHg (95% CI -4.0 to -1.4) compared to 
placebo with a mean change of 0.3 mmHg (95% CI -1.4 to 2.1) (p=0.007), consistent 
with compliance with the medication. We found chin forward position did not alter 
intraocular pressure significantly. There was no difference in NHS health economics 
consumption between Bimatoprost and placebo period. 
Bimatoprost was associated with patient-reported conjunctival hyperemia and 
headache (Supplementary Table 2). Apart from patient-reported side effects, objective 
assessments of photographs were also made by an independent masked assessor. 
Patients treated with Bimatoprost had a higher than placebo detectable skin 
discoloration, eyelashes elongation, and eyelid redness (Supplementary Table 3). 
Only 1 patient (3.2%) developed observable periorbital fat atrophy which was the 
desired effect in this trial (Figure 6). This was a 57-year-old female patient who was a 
current smoker with 5 years history of GO. She was previously treated with IV steroids, 
radiotherapy, cyclosporin and Rituximab. The fat atrophy lasted for 2 months following 
the washout period. In this patient, at baseline the right eye exophthalmometer 
measurement was 23 mm and the left eye was 24 mm. Following 3 months on 
Bimatoprost, there was a reduction of 2 mm of the right eye and 1 mm of the left eye. 






This is the first clinical trial assessing the effects of PGF2α in stable inactive GO. This 
trial did not show any clinical benefit of Bimatoprost on reducing proptosis. This finding 
was confirmed on photographic measurements and despite the effect on IOP and 
appearance changes (lashes elongation, conjunctival hyperemia and skin changes) 
suggesting good compliance. The standard deviation was consistent with power 
calculations suggesting that we were not underpowered and unlikely that the effect 
was missed. This is in contrast with the in vitro findings (20, 21), anecdotal case reports 
in people without GO (6-8) suggesting adipocyte differentiation inhibition with 
Bimatoprost. The findings also contrast with the results obtained with Teprotumumab, 
a human monoclonal antibody inhibitor of IGF-IR shown to reduce proptosis. The 
success of Teprotumumab might be attributed to the fact it was used in active GO and 
it targets a different pathophysiological mechanism. 
The lack of the effects in the primary analysis might be due to several explanations. 
We are fully aware that the 2 main mechanisms of GO are adipogenesis and 
hyaluronan accumulation (22). In the burnt out stage, fibrosis will predominate. The 
topical eye drops might be absorbed less freely due to the inflammatory/fibrosis 
process. In the search for stable disease in order to show the effect of PGF2α, we might 
have chosen the wrong stage of the disease which is predominantly caused by 
hyaluronan deposition or fibrosis rather than adipogenesis. Adipogenesis starts early 
in the disease and it has been shown that it may continue even in the inactive disease 
stage (23). PGF2α inhibits adipogenesis per se but does not affect lipolysis and hence 
has no impact on an already fully mature adipocyte (20). Not all glaucoma patients 




24.1% (24). Some patients with GO have predominantly fat excess whilst the others 
have muscle predominant disease (25). This suggests the possibility of a subgroup of 
subjects that are more susceptible to the effect of Bimatoprost who could be identified 
by screening using orbital imaging.  Perhaps a treatment of 3 months’ duration is not 
long enough to see the intended reduction in proptosis. However, this seems unlikely 
as there was sufficient time to see fat atrophy. Compliance also might be an issue, 
although the changes in IOP on treatment suggest this is unlikely, and we did not find 
a statistically significant treatment effect after adjustment made for compliance using 
a reduction in IOP as a surrogate marker. Periorbital fat atrophy was observed in 1 
subject (3%) of our patient population suggesting that periorbital fat atrophy is different 
from general fat reduction. Perhaps the periorbital effect seen is mediated via a 
different mechanism such as activation on matrix metalloproteinases (26). 
The assessment of exophthalmos was robust with exophthalmometer and supported 
with photographic assessments conducted by an assessor who was masked to the 
treatment phase. In the current study, we had 2 trained assessors. Assessors were 
assigned to the trial patients at each trial visit according to assessors’ availability. To 
reduce inter-rater variation, our assessors were calibrated by multiple 
exophthalmometer readings on the same non-trial subjects in the clinic and 
adjustments were made to ensure their readings were comparable. Photographic 
measurements also provided further independent confirmation of the 
exophthalmometer results.  
The strengths of this trial include its cross-over design with no period or carry-over 
effects. There was good patient retention and good compliance as evidenced by the 




by asking patients and assessors directly and by the independent masked assessor 
on photographic assessment. Assessors guessed treatment allocation incorrectly in 
56.7 % of the patients. Approximately 27% of the patients on placebo thought that the 
prominence of their eyes improved compared to 43% treated with Bimatoprost. Just 
above 40% of the patients in both phases preferred the treatment. 43% of subjects in 
the placebo phase were unsure of treatment allocation and a further 10% guessed 
incorrectly; 29% in the Bimatoprost phase were unsure and 32% guessed incorrectly 
when asked about their treatment allocation suggesting that masking was successful.  
In summary, Bimatoprost treatment over 3 months in inactive GO does not result in 
improvements in proptosis and this information should prevent clinicians trialing this 
approach further and causing side-effects unnecessarily. Future trials should be done 
on early stage GO and active disease. Periorbital fat atrophy appears to be an 
idiosyncratic reaction to Bimatoprost rather than a routine event in inactive GO 
patients. The BIMA study has demonstrated that crossover studies can be performed 
reliably in patients with persistent proptosis due to thyroid eye disease and that this 
study design is acceptable to patients. The BIMA study also has shown that over 60% 
of patients with residual proptosis in thyroid eye disease also have double vision 
(diplopia). IGF-1R antagonists have shown promise in active disease but still only 
surgical treatments are available in burnt out disease. Hence, there are still large 
unmet needs in this patient group. 
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Table 1: Baseline demographics of the study population. Data presented as means 
(standard deviation or range) unless stated otherwise or % (patient number/total). 
.  




Female (%) 83.9 (26/31) 87.5 (14/16) 80.0 (12/15) 
Caucasian (%) 93.5 (29/31) 87.5 (14/16) 100 (15/15) 
Age (years), mean (range) 55.2 (28-74) 55.2 (31-70) 55.2 (28-74) 
BMI (kg/m2) 29.0 (6.5) 28.8 (6.3) 29.2 (7.0) 
Symptom duration before 
diagnosis (months), median 
(IQR) 
4.0 (1-6) 3.5 (2-6.5) 4.0 (1-6) 
GO Duration (years), median 
(IQR) 
7.6 (3.6-12.3) 8.8 (3.5-14.4) 7.1 (4.3-12.3) 
Smokers at diagnosis (%) 74.2 (23/31) 81.2 (13/16) 66.7 (10/15) 
Current smoking (%) 38.7 (12/31) 37.5 (6/16) 40.0 (6/15) 
No. cigarettes/week, median 
(IQR) 
70 (10-105) 70 (2-70) 70 (14-140) 
FT4 (pmol/L), median (IQR) 15.9 (13.5-17.4) 16.7 (15.9-18.4) 13.9 (12.5-15.2) 
TSH (mU/L), median (IQR) 0.87 (0.12-2.6) 0.76 (0.15-1.22)  1.45 (0.12-5.33) 
















































Exophthalmometer (mm) 23.6 (2.5) 24.1 (2.9) 23.1 (1.9) 
Palpebral aperture (mm) 11.1 (2.0) 11.8 (2.0) 10.4 (1.7) 
































The diplopia severity was assessed by Gorman score and GO severity according to EUGOGO 





Table 2: Beta coefficient of Bimatoprost effect on exophthalmometer readings using multilevel 
modeling with each treated patient’s eye within the patient. Minus protocol deviation indicated 
3 patients removed from the analysis due to the stated reason. Minus IOP non-responder 
indicated removal of eyes from analysis with at least a 10% reduction in intraocular pressure 
(surrogate marker to compliance). 





 coefficient 95% CI p value 
All patients 
Model 1 31 50 96 -0.22 -0.75, 0.32 0.424 
Model 2 31 50 96 -0.17 -0.67, 0.32 0.490 
Model 3 31 50 96 -0.16 -0.64, 0.33 0.531 
Minus protocol deviation 
Model 1 28 46 88 -0.06 -0.60, 0.47 0.814 
Model 2 28 46 88 -0.06 -0.56, 0.45 0.827 
Model 3 28 46 88 -0.04 -0.55, 0.46 0.861 
Minus IOP non-responder (10% IOP drop) 
Model 1 27 46 88 -0.37 -0.94, 0.19 0.192 
Model 2 27 46 88 -0.29 -0.81, 0.24 0.283 
Model 3 27 46 88 -0.27 -0.78, 0.25 0.313 
 
Model 1 Adjusted for baseline 
Model 2 Adjusted for baseline, phase and carryover. 
Model 3 Adjusted for baseline phase, carryover and assessors. 






Table 3: Patient-reported ocular side effects.  









10 (32.3) 3 (9.7) 0.029 
Eye pruritus 4 (12.9) 1 (3.2) 0.177 
Eyelid swelling 3 (9.7) 2 (6.5) 0.500 
Visual disturbance 2 (6.5) 0 0.245 
Meibomian cyst  2 (6.5) 2 (6.5) 0.694 
Burning sensation 1 (3.2) 1 (3.2) 0.754 
Eye dryness 1 (3.2) 1 (3.2) 0.500 
Eyelid pigmentation 1 (3.2) 0 0.500 
Conjunctivitis 1 (3.2) 0 0.500 
Foreign body 
sensation 
0 1 (3.2) 0.500 
Eye pain 0 1 (3.2) 0.500 
Ptosis 0 1 (3.2) 0.500 
Difficulty eye 
opening 
0 1 (3.2) 0.500 
The percentage was calculated from the total number of patients in the trial (N=31).  
 
